Hyperphosphatemia

Elevated Phosphate Worsens Inpatient Outcomes Regardless of Renal Function

Publish Date December 13, 2019

In a study of hospitalized patients, increased serum phosphate levels significant increased the risk of acute kidney injury, end-stage renal disease, and death.

Hyperphosphatemia in HD May Raise Risk for Peripheral Artery Disease

Publish Date December 12, 2019

In a study of hemodialysis patients, PAD risk increased nonlinearly with serum phosphate level.

Tenapanor May Improve Uncontrolled Hyperphosphatemia

Publish Date December 11, 2019

By blocking paracellular phosphate transport, tenapanor added to phosphate binders may improve the hyperphosphatemia management in patients on maintenance dialysis, a study found.

Elevated FGF23 Linked to Mortality in Type 2 Diabetes

Publish Date October 10, 2019

In a study, elevated FGF23 was associated with increased risks of major adverse cardiovascular events and mortality in type 2 diabetes patients with normal or mildly impaired kidney function.

Elevated Phosphate May Be Detrimental Even Without CKD

Publish Date October 9, 2019

If confirmed, findings from 2 new studies would have important clinical implications for phosphate intake in the general population.

Very-Low-Phosphate Diet Not Superior for Reducing FGF23

Publish Date October 8, 2019

In a 2-day dietary intervention study, very-low-phosphate and low-phosphate diets decreased fibroblast growth factor 23 levels to a similar degree in patients on hemodialysis, but the very-low-phosphate diets results in greater lowering of phosphorus levels.

Medication Use Low in Non-Dialysis CKD-MBD

Publish Date October 2, 2019

Prescriptions of drugs to treat chronic kidney disease-mineral bone disorders varies widely by country, but it is generally low, a study found.

Ferric Citrate May Lessen Anemia in Advanced CKD

Publish Date July 9, 2019

The phosphate binder ferric citrate coordination complex may mitigate anemia, elevated phosphorus, and FGF23 in patients with advanced CKD, new research suggests.

CV Event Rates Similar for Calcium, Noncalcium Phosphate Binder Users

Publish Date May 15, 2019

In a study, the risks for cardiovascular events and all-cause mortality were only a nonsignificant 4% lower for sevelamer vs calcium acetate recipients older than 65 years initiating hemodialysis.

Staying on Sucroferric Oxyhydroxide May Cut Hospitalization Rate

Publish Date May 10, 2019

Hemodialysis patients who stayed on the phosphate binder sucroferric oxyhydroxide for 2 years had fewer hospitalizations those who switched to another binder for 2 years.